Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1

Mathieu Métifiot; Samir Amrane; Jean Louis Mergny; Marie Line Andreola

doi:10.1016/j.biochi.2015.09.009

Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1

Mathieu Métifiot
, Samir Amrane
, Jean Louis Mergny
, Marie Line Andreola

Univ. Bordeaux

Research output: Contribution to journal › Article › peer-review

Abstract

During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.

Original language	English
Pages (from-to)	173-175
Number of pages	3
Journal	Biochimie
Volume	118
DOIs	https://doi.org/10.1016/j.biochi.2015.09.009
Publication status	Published - 1 Nov 2015
Externally published	Yes

Keywords

Anticancer
Antiviral
G-quadruplexes
Nucleolin
Zintevir

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biochi.2015.09.009

Cite this

@article{f6626d94c3ac429eb820fe4e2cfe8a85,

title = "Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1",

abstract = "During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.",

keywords = "Anticancer, Antiviral, G-quadruplexes, Nucleolin, Zintevir",

author = "Mathieu M{\'e}tifiot and Samir Amrane and Mergny, \{Jean Louis\} and Andreola, \{Marie Line\}",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.biochi.2015.09.009",

language = "English",

volume = "118",

pages = "173--175",

journal = "Biochimie",

issn = "0300-9084",

}

TY - JOUR

T1 - Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1

AU - Métifiot, Mathieu

AU - Amrane, Samir

AU - Mergny, Jean Louis

AU - Andreola, Marie Line

PY - 2015/11/1

Y1 - 2015/11/1

N2 - During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.

AB - During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.

KW - Anticancer

KW - Antiviral

KW - G-quadruplexes

KW - Nucleolin

KW - Zintevir

U2 - 10.1016/j.biochi.2015.09.009

DO - 10.1016/j.biochi.2015.09.009

M3 - Article

C2 - 26363100

AN - SCOPUS:84942123712

SN - 0300-9084

VL - 118

SP - 173

EP - 175

JO - Biochimie

JF - Biochimie

ER -

Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this